The breast cancer cell lines used in this study included one (T47D) with mutant p53 and one (LCC9) with acquired endocrine resistance, indicating that CEP-1347 or other MLK inhibitors may provide useful therapeutics for a wide range of ER+ breast tumors. Here, TP53 is linked to breast cancer.